DOESUM, Jaap A van, Jon SALMANTON-GARCIA, Francesco MARCHESI, Di Blasi ROBERTA, Iker FALCES-ROMERO, Alba CABIRTA, Francesca FARINA, Caroline BESSON, Barbora WEINBERGEROVÁ, Van Praet JENS, Martin SCHOENLEIN, Alberto LOPEZ-GARCIA, Sylvain LAMURE, Anna GUIDETTI, De Ramon-Sanchez CRISTINA, Josip BATINIC, Eleni GAVRIILAKI, Athanasios TRAGIANNIDIS, Maria Chiara TISI, Gaetan PLANTEFEVE, Verena PETZER, Irati ORMAZABAL-VELEZ, de Almeida Joyce MARQUES, Monia MARCHETTI, Johan MAERTENS, Marina MACHADO, Austin KULASEKARARAJ, Jose-angel HERNANDEZ-RIVAS, Maria Gomes da SILVA, Noemi FERNANDEZ, Ildefonso ESPIGADO, Lubos DRGONA, Giulia DRAGONETTI, Elisabetta METAFUNI, Maria CALBACHO, Ola BLENNOW, Dominik WOLF, van Anrooij BJORN, Raquel Nunes RODRIGUES, Anna NORDLANDER, Juan-Alberto MARTIN-GONZALEZ, Raphael LIEVIN, Moraima JIMENEZ, Stefanie K GRAFE, Ramon GARCIA-SANZ, Raul CORDOBA, Laman RAHIMLI, van Meerten TOM, Oliver A CORNELY and Livio PAGANO. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey. Blood advances. AMSTERDAM: ELSEVIER, 2023, vol. 7, No 11, p. 2645-2655. ISSN 2473-9529. Available from: https://dx.doi.org/10.1182/bloodadvances.2022009578.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
Authors DOESUM, Jaap A van, Jon SALMANTON-GARCIA, Francesco MARCHESI, Di Blasi ROBERTA, Iker FALCES-ROMERO, Alba CABIRTA, Francesca FARINA, Caroline BESSON, Barbora WEINBERGEROVÁ (203 Czech Republic, belonging to the institution), Van Praet JENS, Martin SCHOENLEIN, Alberto LOPEZ-GARCIA, Sylvain LAMURE, Anna GUIDETTI, De Ramon-Sanchez CRISTINA, Josip BATINIC, Eleni GAVRIILAKI, Athanasios TRAGIANNIDIS, Maria Chiara TISI, Gaetan PLANTEFEVE, Verena PETZER, Irati ORMAZABAL-VELEZ, de Almeida Joyce MARQUES, Monia MARCHETTI, Johan MAERTENS, Marina MACHADO, Austin KULASEKARARAJ, Jose-angel HERNANDEZ-RIVAS, Maria Gomes da SILVA, Noemi FERNANDEZ, Ildefonso ESPIGADO, Lubos DRGONA, Giulia DRAGONETTI, Elisabetta METAFUNI, Maria CALBACHO, Ola BLENNOW, Dominik WOLF, van Anrooij BJORN, Raquel Nunes RODRIGUES, Anna NORDLANDER, Juan-Alberto MARTIN-GONZALEZ, Raphael LIEVIN, Moraima JIMENEZ, Stefanie K GRAFE, Ramon GARCIA-SANZ, Raul CORDOBA, Laman RAHIMLI, van Meerten TOM, Oliver A CORNELY and Livio PAGANO.
Edition Blood advances, AMSTERDAM, ELSEVIER, 2023, 2473-9529.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30205 Hematology
Country of publisher Netherlands
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 7.500 in 2022
RIV identification code RIV/00216224:14110/23:00133401
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1182/bloodadvances.2022009578
UT WoS 001023671100001
Keywords in English SARS-CoV-2 vaccination; post–CD19-directed CAR T-cell therapy
Tags 14110212, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 2/2/2024 09:14.
Abstract
Patients with previous CD19-directed chimeric antigen receptor (CAR) T-cell therapy have a prolonged vulnerability to viral infections. Coronavirus disease 2019 (COVID-19) has a great impact and has previously been shown to cause high mortality in this population. Until now, real-world data on the impact of vaccination and treatment on patients with COVID-19 after CD19-directed CAR T-cell therapy are lacking. Therefore, this multicenter, retrospective study was conducted with data from the EPICOVIDEHA survey. Sixty-four patients were identified. The overall mortality caused by COVID-19 was 31%. Patients infected with the Omicron variant had a significantly lower risk of death due to COVID-19 compared with patients infected with previous variants (7% vs 58% [P = .012]). Twenty-six patients were vaccinated at the time of the COVID-19 diagnosis. Two vaccinations showed a marked but unsignificant reduction in the risk of COVID-19-caused mortality (33.3% vs 14.2% [P = .379]). In addition, the course of the disease appears milder with less frequent intensive care unit admissions (39% vs 14% [P = .054]) and a shorter duration of hospitalization (7 vs 27.5 days [P = .022]). Of the available treatment options, only monoclonal antibodies seemed to be effective at reducing mortality from 32% to 0% (P = .036). We conclude that survival rates of CAR T-cell recipients with COVID-19 improved over time and that the combination of prior vaccination and monoclonal antibody treatment significantly reduces their risk of death. This trial was registered at www. clinicaltrials.gov as #NCT04733729.
PrintDisplayed: 21/7/2024 05:51